BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, ...
GlobalData on MSN
Life Bio receives FDA approval for ER-100 clinical trial
The Phase I trial will recruit participants who have been diagnosed with non-arteritic anterior ischaemic optic neuropathy and open-angle glaucoma.
Life Biosciences plans to begin human clinical trials of a cellular rejuvenation therapy in optic neuropathies after ...
Morning Overview on MSN
Scientists trial shocking ER-100 drug that could reverse human aging
For decades, the idea of a drug that could rewind aspects of human aging has belonged more to science fiction than hospital formularies. That boundary is starting to blur as a gene therapy called ...
Add Yahoo as a preferred source to see more of our stories on Google. Researchers say they have uncovered a link between semaglutide -- the active ingredient in Ozempic and Wegovy -- and the eye ...
Glaucoma specialists are marking their calendars for January 31, 2026—when the 2nd International Glaucoma Symposium will take ...
Please provide your email address to receive an email when new articles are posted on . Traumatic optic nerve head avulsion and traumatic optic neuropathy are serious and can be visually devastating.
Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay News — ...
Traumatic optic neuropathy is visual loss caused by trauma to the optic nerve. Injuries, classified as direct or indirect, are also characterized by location. Intracanalicular optic nerve injury is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results